Tamoxifen as a new therapeutic tool for neutrophilic lung inflammation

Respirology

Volumn 21, Issue 1, 2016, Pages 112-118

  Perez, Barbara ^a   Henriquez, Claudio ^a   Sarmiento, Jose ^a   Morales, Natalia ^a   Folch, Hugo ^a   Galesio, Juan S ^a   Uberti, Benjamin ^a   Morán, Gabriel ^a  

^a UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

Author keywords

early apoptosis; equine recurrent airway obstruction; neutrophil; neutrophilic asthma; tamoxifen

Indexed keywords

ALLERGEN; ASPARTATE AMINOTRANSFERASE; CREATININE; DEXAMETHASONE; GAMMA GLUTAMYLTRANSFERASE; GLUCOCORTICOID; GLUTAMATE DEHYDROGENASE; NITROGEN; TAMOXIFEN; UREA; ANTIINFLAMMATORY AGENT; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

AIRWAY OBSTRUCTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; ASPERGILLUS FUMIGATUS; ASTHMA; CELL ISOLATION; CELL VIABILITY; CONTROLLED STUDY; CYTOLOGY; GRANULOCYTE; HORSE; HORSE DISEASE; LEUKOCYTE; LUNG LAVAGE; MUCOUS CELL; NEUTROPHIL; NEUTROPHIL COUNT; NEUTROPHILIC PNEUMONIA; NONHUMAN; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; ANIMAL; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODEL; DRUG EFFECTS; HUMAN; IMMUNOLOGY; PATHOLOGY;

AIRWAY OBSTRUCTION; ALLERGENS; ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; ASTHMA; BRONCHOALVEOLAR LAVAGE FLUID; DEXAMETHASONE; DISEASE MODELS, ANIMAL; HORSES; HUMANS; NEUTROPHILS; PNEUMONIA; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 84952870684     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12664     Document Type: Article

References (53)

1. Lugogo NL, Kraft M,. Epidemiology of asthma. Clin. Chest Med. 2006; 27: 1-15.
2. Erle DJ, Sheppard D,. The cell biology of asthma. J. Cell Biol. 2014; 205: 621-631.
3. Douwes J, Gibson P, Pekkanen J, Pearce N,. Non-eosinophilic asthma: importance and possible mechanisms. Thorax 2002; 57: 643-648.
4. Holgate ST,. Pathogenesis of asthma. Clin. Exp. Allergy 2008; 38: 872-897.
5. Kato T, Takeda Y, Nakada T, Sendo F,. Inhibition by dexamethasone of human neutrophil apoptosis in vitro. Nat. Immun. 1995; 14: 198-208.
6. Liles WC, Dale DC, Klebanoff SJ,. Glucocorticoids inhibit apoptosis of human neutrophils. Blood 1995; 86: 3181-3188.
7. Cox G, Austin RC,. Dexamethasone-induced suppression of apoptosis in human neutrophils requires continuous stimulation of new protein synthesis. J. Leukoc. Biol. 1997; 61: 224-230.
8. Saffar AS, Dragon S, Ezzati P, Shan L, Gounni AS,. Phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase regulate induction of Mcl-1 and survival in glucocorticoid-treated human neutrophils. J. Allergy Clin. Immunol. 2008; 121: 492-498, e10.
9. Fahy JV,. Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies. Proc. Am. Thorac. Soc. 2009; 6: 256-259.
10. Akgul C, Moulding DA, Edwards SW,. Molecular control of neutrophil apoptosis. FEBS Lett. 2001; 487: 318-322.
11. Sarmiento J, Perez B, Morales N, Henriquez C, Vidal L, Folch H, Galecio JS, Moran G,. Apoptotic effects of tamoxifen on leukocytes from horse peripheral blood and bronchoalveolar lavage fluid. Vet. Res. Commun. 2013; 37: 333-338.
12. Sthoeger ZM, Zinger H, Mozes E,. Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of (NZBxNZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies. Ann. Rheum. Dis. 2003; 62: 341-346.
13. Behjati S, Frank MH,. The effects of tamoxifen on immunity. Curr. Med. Chem. 2009; 16: 3076-3080.
14. Sereda D, Werth VP,. Improvement in dermatomyositis rash associated with the use of antiestrogen medication. Arch. Dermatol. 2006; 142: 70-72.
15. Cushman M, Costantino JP, Tracy RP, Song K, Buckley L, Roberts JD, Krag DN,. Tamoxifen and cardiac risk factors in healthy women: suggestion of an anti-inflammatory effect. Arterioscler. Thromb. Vasc. Biol. 2001; 21: 255-261.
16. Babina M, Kirn F, Hoser D, Ernst D, Rohde W, Zuberbier T, Worm M,. Tamoxifen counteracts the allergic immune response and improves allergen-induced dermatitis in mice. Clin. Exp. Allergy 2010; 40: 1256-1265.
17. De M, Jaap A, Dempster J,. Tamoxifen therapy in steroid-resistant Riedels disease. Scott. Med. J. 2002; 47: 12-13.
18. Leclere M, Lavoie-Lamoureux A, Lavoie JP,. Heaves, an asthma-like disease of horses. Respirology 2011; 16: 1027-1046.
19. Bullone M, Lavoie JP,. Asthma 'of horses and men'-How can equine heaves help us better understand human asthma immunopathology and its functional consequences? Mol. Immunol. 2015; 66: 97-105.
20. Bartner LR, Robinson NE, Kiupel M, Tesfaigzi Y,. Persistent mucus accumulation: a consequence of delayed bronchial mucous cell apoptosis in RAO-affected horses? Am. J. Physiol. Lung Cell. Mol. Physiol. 2006; 291: L602-609.
21. Holcombe SJ, Jackson C, Gerber V, Jefcoat A, Berney C, Eberhardt S, Robinson NE,. Stabling is associated with airway inflammation in young Arabian horses. Equine Vet. J. 2001; 33: 244-249.
22. Robinson NE,. International workshop on equine chronic airway disease. Michigan State University 16-18 June 2000. Equine Vet. J. 2001; 33: 5-19.
23. Marti E, Gerber H, Essich G, Oulehla J, Lazary S,. The genetic basis of equine allergic diseases. 1. Chronic hypersensitivity bronchitis. Equine Vet. J. 1991; 23: 457-460.
24. Cordeau ME, Joubert P, Dewachi O, Hamid Q, Lavoie JP,. IL-4, IL-5 and IFN-gamma mRNA expression in pulmonary lymphocytes in equine heaves. Vet. Immunol. Immunopathol. 2004; 97: 87-96.
25. Horohov DW, Beadle RE, Mouch S, Pourciau SS,. Temporal regulation of cytokine mRNA expression in equine recurrent airway obstruction. Vet. Immunol. Immunopathol. 2005; 108: 237-245.
26. Lavoie JP, Maghni K, Desnoyers M, Taha R, Martin JG, Hamid QA,. Neutrophilic airway inflammation in horses with heaves is characterized by a Th2-type cytokine profile. Am. J. Respir. Crit. Care Med. 2001; 164: 1410-1413.
27. Rush BR, Raub ES, Rhoads WS, Flaminio MJ, Matson CJ, Hakala JE, Gillespie JR,. Pulmonary function in horses with recurrent airway obstruction after aerosol and parenteral administration of beclomethasone dipropionate and dexamethasone, respectively. Am. J. Vet. Res. 1998; 59: 1039-1043.
28. Morán G, Ojeda G, Diedrichs K, Ortloff A, Barria M, Folch H,. Inhalation of Aspergillus fumigatus spores induces airway inflammation in mice in a similar manner as observed in recurrent airway obstruction in horses. Arch. Med. Vet. 2011; 43: 163-171.
29. Clarke AG, Madelin T,. Technique for assessing respiratory health hazard from hay and other source materials. Equine Vet. J. 1987; 19: 442-447.
30. Robinson NE, Olszewski MA, Boehler D, Berney C, Hakala J, Matson C, Derksen FJ,. Relationship between clinical signs and lung function in horses with recurrent airway obstruction (heaves) during a bronchodilator trial. Equine Vet. J. 2000; 32: 393-400.
31. Gerber V, Straub R, Marti E, Hauptman J, Herholz C, King M, Imhof A, Tahon L, Robinson NE,. Endoscopic scoring of mucus quantity and quality: observer and horse variance and relationship to inflammation, mucus viscoelasticity and volume. Equine Vet. J. 2004; 36: 576-582.
32. Stonard MD,. Assessment of nephrotoxicity. In:, Evans GO, (ed) Animal Clinical Chemistry. Taylor & Francis, London, 2005; 87-88.
33. Eckersall PD,. Proteins, proteomics, and the dysproteinemias. In:, Kaneko JJ, Harvey JW, Bruss ML, (eds) Clinical Biochemistry Domestic Animals. Elsevier, Oxford, 2008; 134.
34. Robinson NE, Berney C, Eberhart S, deFeijter-Rupp HL, Jefcoat AM, Cornelisse CJ, Gerber VM, Derksen FJ,. Coughing, mucus accumulation, airway obstruction, and airway inflammation in control horses and horses affected with recurrent airway obstruction. Am. J. Vet. Res. 2003; 64: 550-557.
35. Rush BR, Flaminio MJ, Matson CJ, Hakala JE, Shuman W,. Cytologic evaluation of bronchoalveolar lavage fluid from horses with recurrent airway obstruction after aerosol and parenteral administration of beclomethasone dipropionate and dexamethasone, respectively. Am. J. Vet. Res. 1998; 59: 1033-1038.
36. Robinson NE, Jackson C, Jefcoat A, Berney C, Peroni D, Derksen FJ,. Efficacy of three corticosteroids for the treatment of heaves. Equine Vet. J. 2002; 34: 17-22.
37. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB,. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004; 23: 9247-9258.
38. Bureau F, Bonizzi G, Kirschvink N, Delhalle S, Desmecht D, Merville MP, Bours V, Lekeux P,. Correlation between nuclear factor-kappaB activity in bronchial brushing samples and lung dysfunction in an animal model of asthma. Am. J. Respir. Crit. Care Med. 2000; 161: 1314-1321.
39. Bureau F, Delhalle S, Bonizzi G, Fievez L, Dogne S, Kirschvink N, Vanderplasschen A, Merville MP, Bours V, Lekeux P,. Mechanisms of persistent NF-kappa B activity in the bronchi of an animal model of asthma. J. Immunol. 2000; 165: 5822-5830.
40. Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, Pigatto F, Pesci-Feltri A, Robertson C, Serrano D, Pelosi G, Decensi A, Lien EA,. Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin. Cancer Res. 2004; 10: 2336-2343.
41. Ray A, Ficek M,. Immunomodulatory effects of anti-estrogenic drugs. Acta Pharm. 2012; 62: 141-155.
42. Clarke M, Collins R, Davies C,. Tamoxifen for early breast cancer: an overview of the randomized trial. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 351: 1451-1467.
43. Jordan VC,. Tamoxifen: too much of a good thing? J. Clin. Oncol. 1999; 17: 2629-2630.
44. Lee KH, Ward BA, Desta Z, Flockhart DA, Jones DR,. Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2003; 791: 245-253.
45. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA,. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst. 2003; 95: 1758-1764.
46. Maltoni C, Minardi F, Belpoggi F, Pinto C, Lenzi A, Filippini F,. Experimental results on the chemopreventive and side effects of tamoxifen using a human-equivalent animal model. In:, Maltoni C, Soffritti M, Davis W, (eds) The Scientific Bases of Cancer Chemoprevention. Elsevier Science, Amsterdam, 1996; 197-207.
47. Decensi A, Robertson C, Viale G, Pigatto F, Johansson H, Kisanga ER, Veronesi P, Torrisi R, Cazzaniga M, Mora S, et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J. Natl. Cancer Inst. 2003; 95: 779-790.
48. Haslett C,. Granulocyte apoptosis and its role in the resolution and control of lung inflammation. Am. J. Respir. Crit. Care Med. 1999; 160: S5-11.
49. Brazil TJ, Dagleish MP, McGorum BC, Dixon PM, Haslett C, Chilvers ER,. Kinetics of pulmonary neutrophil recruitment and clearance in a natural and spontaneously resolving model of airway inflammation. Clin. Exp. Allergy 2005; 35: 854-865.
50. Ortega-Gomez A, Perretti M, Soehnlein O,. Resolution of inflammation: an integrated view. EMBO Mol. Med. 2013; 5: 661-674.
51. Craig VC,. New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids 2007; 72: 829-842.
52. Robinson SP, Langan-Fahey SM, Johnson DA, Jordan VC,. Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab. Dispos. 1991; 19: 36-43.
53. Cox G,. Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. J. Immunol. 1995; 154: 4719-4725.